Abstract: Systems and methods for operating an engine that includes an exhaust gas heat recovery system are described. The system may reduce engine warm-up time and increase an amount of time an engine of a hybrid vehicle is deactivated while the hybrid vehicle is powered by a motor. In one example, a phase change material selectively stores and releases exhaust gas energy from and engine to improve vehicle operation.

Abstract: Disclosed are compounds of the following formula: in which R1, R2, R5, R6, R7, R31, u, and X are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.

Abstract: Systems and methods for operating an engine that includes an exhaust gas heat recovery system are described. The system may reduce engine warm-up time and increase an amount of time an engine of a hybrid vehicle is deactivated while the hybrid vehicle is powered by a motor. In one example, a phase change material selectively stores and releases exhaust gas energy from and engine to improve vehicle operation.

Abstract: Compounds are provided for use with glucokinase that comprise the formula: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Abstract: A system includes one or more processors configured to receive a route and receive power-usage-affecting variables. The processor(s) are further configured to break the route into a number of segments. For each segment, the processors are configured to lookup a predetermined power usage estimate, based on the received variables. Also, the processors are configured to present total estimated power usage over the route based on accumulated power usage estimates for each segment.

Abstract: An electric vehicle powertrain according to an exemplary aspect of the present disclosure includes, among other things, a thermal barrier secured relative to an engine, a transaxle, or both to retain thermal energy generated during operation of an electric vehicle.

Abstract: Systems and methods for operating an engine that includes an exhaust gas heat recovery system are described. The system may selectively or contemporaneously supply energy from engine exhaust gas to generate electricity or warm the engine. In one example, exhaust gas energy raises a temperature of a heat transfer medium and the heat transfer medium is routed to an engine coolant heat exchanger or an expander via a bypass valve.

Abstract: Systems and methods for operating an engine that includes an exhaust gas heat recovery system are described. The system may reduce engine warm-up time and increase an amount of time an engine of a hybrid vehicle is deactivated while the hybrid vehicle is powered by a motor. In one example, a phase change material selectively stores and releases exhaust gas energy from and engine to improve vehicle operation.

Abstract: Disclosed are compounds of the following formula: in which R1, R2, R3, R4, R5, R6, R7, X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.

Abstract: Disclosed are compounds of the following formula: in which R1, R2, R3, R4, R5, R6, R7, and X, are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.

Abstract: Compounds of the following formula are provided for use in inhibiting Poly (ADP-ribose) Polymerase (PARP): wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds.

Abstract: Compounds are provided for use with glucokinase that comprise the formula: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Abstract: A computer-implemented method includes establishing a road network model on which a plurality of simulated vehicles may be run. The method also includes setting up a plurality of scenarios under which vehicle driving conditions vary to be run on the road network model. The illustrative method includes receiving energy usage related data for a plurality of simulated vehicles run in at least one of the plurality of scenarios on the road network model. The method further includes calculating a total energy consumption for each of the vehicles. The method additionally includes repeating the receiving and calculating steps to determine how various elements of the road network model and scenarios effect vehicle energy consumption.

Abstract: Compounds are provided for use with glucokinase that comprise the formula: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Abstract: Disclosed are compounds of the following formula: in which R1, R2, R3, R4, R5, R6, R7, X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.

Abstract: A method for controlling a vehicle including a fuel cell system and an energy storage unit includes, if the fuel cell system is charging the energy storage unit, determining an average ratio of (i) a change in energy stored in the energy storage unit and (ii) a mass of hydrogen consumed by the fuel cell system to generate the change in energy stored in the energy storage unit. The method also includes, if the fuel cell system is not charging the energy storage unit, selecting a target operating power for the fuel cell system based on vehicle power demand and the determined ratio that sufficiently minimizes drive cycle hydrogen consumption by the fuel cell system.

Abstract: The present invention is directed to cationic nanoparticles, methods to make them, and the use of compositions containing said nanoparticles in personal care compositions or formulations. The nanoparticles are useful in personal care applications and impart antimicrobial properties to home and personal care products containing them. These cationic nanoparticles also contribute useful conditioning properties to hair-care and skin-care products.

Abstract: Disclosed are compounds of the following formula: in which R1, R2, R6, R7, R12, X, and q are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.

Abstract: A computer-implemented method includes establishing a road network model on which a plurality of simulated vehicles may be run. The method also includes setting up a plurality of scenarios under which vehicle driving conditions vary to be run on the road network model. The illustrative method includes receiving energy usage related data for a plurality of simulated vehicles run in at least one of the plurality of scenarios on the road network model. The method further includes calculating a total energy consumption for each of the vehicles. The method additionally includes repeating the receiving and calculating steps to determine how various elements of the road network model and scenarios effect vehicle energy consumption.

Abstract: Compounds are provided for use with glucokinase that comprise the formula: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.